Asclepion-Meditec AG english

Asclepion optimises costs structure - Sale of Floss site in Bavaria

Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
---------------------------------------------------------------------------
-----

Asclepion optimises costs structure - Sale of Floss site in Bavaria

- US company Biolase Inc. acquires site and takes over entire workforce
- Positive economic effects of the deal anticipated as early as February
2002
- Consistent implementation of cost-cutting measures announced earlier
will be
  continued

Jena, 6 February 2002 - As of 1 February 2002 Asclepion-Meditec AG
(securities
code no. 531 370) has sold its production facility in Floss near Munich to
the
European subsidiary of US-based Biolase Technology, Inc. (Nasdaq symbol:
BLTI)
which showed a tremendous growth in its business development over the past
quarters. This step is part of a set of measures introduced in the past
financial year and aimed at optimising the cost structure. The sale
agreement
also guarantees job security at the plant, as Biolase has taken over the
entire
workforce of ten. Both sides agreed not to disclose the sale price.

Asclepion anticipates that the positive economic impact of the sale of the
Floss
 facility will be effective as early as February 2002. These include a
considerable improvement in the group's cost structure and reduced
complexity
costs resulting from the streamlined site structure.

At the Floss site, Asclepion produced small numbers of standard lasers and
provided services. The move to Asclepion's new company building at Jena
meant
that production processes and other internal workflows were optimised, so
that
these services can now be provided at Jena.

Asclepion is looking to press ahead with its cost-cutting and optimisation
programme in the future. Besides optimising the location structure and the
number of employees, this also involves reducing overheads and considerably
streamlining internal processes. These measures had already started to
produce
positive results in the fourth quarter of the last financial year.

Asclepion-Meditec AG

Asclepion-Meditec AG (Securities Id. No.: 531 370, symbol: AFX,
www.asclepion.com) with subsidiaries in the United Kingdom, Italy and the
USA is
 one of the global technology and innovation leaders of laser medicine.

Asclepion launched the world's first excimer laser for refractive surgery
in
1986. Other world firsts include the YAG laser for photo disruption (1981)
and
the erbium dental laser (1991).

The company is the largest European manufacturer of laser systems for
ophthalmology (vision correction and eye disease), dermatology (aesthetic
applications like laser hair removal or tattoo removal) and dentistry
(virtually
 pain-free caries treatment). Furthermore the company has an extensive
worldwide
 service network.

Contact:
Asclepion-Meditec AG
Jens Brajer
Investor Relations/Public Relations
Phone: +49 (0) 36 41 / 2 20 - 1 05
Fax: +49 (0) 36 41 / 2 20 - 1 02
E-mail: jb@asclepion.com


end of message, (c)DGAP 08.02.2002